Xencor (NASDAQ:XNCR) Trading Down 5.4% – Should You Sell?

Shares of Xencor, Inc. (NASDAQ:XNCR) fell 5.4% during trading on Tuesday . The stock traded as low as $8.21 and last traded at $7.92. 107,457 shares changed hands during trading, a decline of 82% from the average session volume of 604,578 shares. The stock had previously closed at $8.37.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Wells Fargo & Company cut their price target on Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a report on Friday, February 28th. StockNews.com downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.38.

Xencor Trading Down 7.9 %

The company has a market capitalization of $543.26 million, a price-to-earnings ratio of -2.41 and a beta of 0.90. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. The business’s 50-day simple moving average is $14.29 and its 200-day simple moving average is $19.59.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.19. The firm had revenue of $52.79 million for the quarter, compared to analysts’ expectations of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. On average, research analysts expect that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Xencor

A number of institutional investors and hedge funds have recently added to or reduced their stakes in XNCR. RTW Investments LP grew its holdings in Xencor by 317.9% during the fourth quarter. RTW Investments LP now owns 2,402,883 shares of the biopharmaceutical company’s stock valued at $55,218,000 after purchasing an additional 1,827,883 shares during the period. BVF Inc. IL grew its holdings in shares of Xencor by 169.3% in the 4th quarter. BVF Inc. IL now owns 2,288,760 shares of the biopharmaceutical company’s stock valued at $52,596,000 after buying an additional 1,438,760 shares during the period. Nuveen Asset Management LLC increased its position in shares of Xencor by 452.4% in the 4th quarter. Nuveen Asset Management LLC now owns 837,082 shares of the biopharmaceutical company’s stock valued at $19,236,000 after buying an additional 685,557 shares in the last quarter. Finepoint Capital LP acquired a new stake in Xencor during the 4th quarter worth $15,167,000. Finally, Vanguard Group Inc. raised its stake in Xencor by 5.5% during the 4th quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company’s stock worth $184,239,000 after buying an additional 418,040 shares during the period.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.